Missouri Senate Bill SB1263

Missouri 2026 Regular Session

• Introduced: 1/7/26
• Introduced: 12/31/69
• Refer: 1/27/26

Caption

SB 1263

Summary

SB 1263 would amend Missouri’s MO HealthNet statute and create a new insurance coverage mandate known as “Colton’s Law.” On the Medicaid side, the bill adds coverage for medically necessary physician-prescribed treatment for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS). The bill specifies that covered treatment may include antibiotics, medications, behavioral therapies, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy. The bill also states that health carriers and health benefit plans issued or renewed in Missouri on or after January 1, 2027, must cover medically necessary treatment for PANDAS and PANS. The coverage cannot be subject to higher cost-sharing than comparable benefits, must be authorized in a timely manner, and cannot be denied or delayed solely because the patient previously received similar treatment or was diagnosed under a different name such as autoimmune encephalopathy. The bill further says coverage should follow best-practice recommendations from a professional consortium and may not be limited by lifetime caps or policy periods, though insurers may request treatment notes and expected duration/outcome information.

Impact

SB 1263 would revise section 208.152 of the Missouri statutes governing MO HealthNet benefits and add a new section, 376.1293, to the insurance code. In practical terms, it would expand Medicaid and private health plan coverage obligations for PANDAS and PANS treatment, affecting MO HealthNet, health carriers, health benefit plans, providers, and patients seeking these services. It also creates a statutory framework for what treatments must be covered and how those benefits are administered, while excluding certain supplemental insurance products from the mandate.

Sentiment

The bill’s framing as “Colton’s Law” and its focus on pediatric disorders suggest a sympathetic, patient-centered purpose, and the text is written to ensure access to treatment rather than restrict it. No committee transcripts or recorded votes were provided, so there is no direct evidence of debate, amendments, or formal support/opposition in the available record. Based on the bill language alone, the overall sentiment appears favorable toward expanding coverage for affected children and families.

Contention

The main policy issue likely to generate contention is the scope and medical basis of mandated coverage for PANDAS and PANS, including which treatments qualify as medically necessary and how best-practice standards are defined. Insurers may be concerned about the breadth of required benefits, the prohibition on denial based on prior treatment or alternate diagnoses, and the potential cost impact of therapies such as IVIG or plasma exchange. On the Medicaid side, any expansion of covered services may raise appropriation and budget concerns, while providers and patient advocates would likely support the mandate as improving access to care.